Novartis Cholesterol Drug Trial Fails, Sector Under Pressure

The news indicates that Novartis' cholesterol drug trial has failed, putting pressure on the sector. This could have a negative sector-wide impact on companies operating in the cardiovascular space, such as LLY. Technical indicators also present a weak outlook, with RSI at 44 in the lower-neutral zone, MACD negative, and price action below the SMA20 and SMA50. In the short term, selling pressure is likely to persist, but since the news is not directly specific to LLY, the impact may be limited. Therefore, the direction is bearish, but the confidence level is maintained at moderate.

The news indicates that Novartis's cholesterol drug trial has failed, putting the sector under pressure. This negative development could create short-term selling pressure on the stock. Technically, the price is below the 20-day moving average, and the RSI is in neutral territory, with MACD below the signal line, indicating weakness. However, since the price remains above the 50-day average, the decline is likely to be limited. A downward movement can be expected in the short term.

The failure of Novartis's cholesterol drug trial could strengthen Amgen's competitive position in the cholesterol space and may have a short-term positive impact on the stock. Technically, the RSI at 45.77 is in neutral territory, and the MACD is below the signal line, while the price is slightly below the 20-day SMA but above the 50-day SMA, presenting a balanced outlook. Although the news creates sector-wide pressure, it may be perceived as a potential gain for Amgen. However, with the price consolidating around $437 and no volume data, upside movement is expected to be limited. In the short term, the probability of a rebound toward the $440-$445 resistance zone is moderate.